Precigen To Present Late-Breaking Abstract For Pivotal Phase 2 Study Data For PRGN-2012 AdenoVerse Immunotherapy For The Treatment Of Patients With Recurrent Respiratory Papillomatosis At The 2024 ASCO Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Precigen, Inc. (NASDAQ:PGEN) announced that clinical data from its Phase 2 study of PRGN-2012 AdenoVerse immunotherapy for treating recurrent respiratory papillomatosis (RRP) will be presented at the 2024 ASCO Annual Meeting. This novel treatment has shown to lead to complete and durable responses in RRP patients.
April 24, 2024 | 2:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Precigen's announcement of presenting pivotal Phase 2 study data for PRGN-2012 at the 2024 ASCO Meeting highlights a significant advancement in RRP treatment.
The announcement of presenting late-breaking abstract data at a prestigious conference like ASCO can be seen as a positive development, indicating strong confidence in the study results. This could lead to increased investor interest and potentially positive movement in Precigen's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100